Tools to access and analyze un reduced mass spectrometry data to accelerate acce...
Tools to access and analyze un reduced mass spectrometry data to accelerate access to biotherapeutics
Biotherapeutics, such as monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs), constitute an increasingly important class of molecular drugs. Accelerating our society’s access to novel biotherapeutics-based therapies a...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
iSTantibody
An innovative seamless approach for the mass spectrometry...
71K€
Cerrado
PTA2017-13807-I
Análisis proteómicos mediante técnicas de espectrometria de...
39K€
Cerrado
IMMUNO-MONITORING
ELECTROCHEMICAL DNA-BASED SENSORS FOR IMMUNOTHERAPY MONITORI...
150K€
Cerrado
EQC2019-005439-P
Adquisición de un espectrómetro de masas de movilidad iónica...
823K€
Cerrado
iLCA
Intelligent Live Cell Analysis iLCA to transform disease m...
3M€
Cerrado
Información proyecto A2MStools
Duración del proyecto: 12 meses
Fecha Inicio: 2021-03-08
Fecha Fin: 2022-03-31
Líder del proyecto
SPECTROSWISS SARL
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
100K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Biotherapeutics, such as monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs), constitute an increasingly important class of molecular drugs. Accelerating our society’s access to novel biotherapeutics-based therapies and diagnostic tests for existing and new clinical indications, including those caused by COVID-19, is critical. The exceptional specificity and selectivity of mass spectrometry (MS) renders this analytical technique a powerful tool in development of biotherapeutics-based drugs and clinical diagnostics. Nevertheless, even Orbitrap Fourier transform mass spectrometry (FTMS), which dominates the high-performance MS field, may demonstrate limited performance in structural analysis of the very complex mAbs and ADCs. Indeed, while the user-accessible Orbitrap data (processed mass spectra with reduced information) may be of a sufficient quality and information content for small molecule and isolated proteins analysis, it is not for the complex biotherapeutics. We identified the limiting factor that inhibits biotherapeutics structure analysis being the absence of hardware and software tools to acquire (access and provide to the end-users) and analyze the un-reduced data (e.g., time-domain signals or transients). With these tools in hands, the end-users would be able to increase performance and productivity of their biopharma workflows on the Orbitraps (e.g., leading to increased sensitivity and resolution, and thus leading to faster identification of more species and their deeper sequencing), as well as create novel workflows, not possible otherwise. The A2MStools (access & analysis MS tools) aims to address this limitation by: (i) providing access to the currently unavailable un-reduced data (transients) for the Orbitraps FTMS platforms with enabled BioPharma capabilities, and (ii) empowering analytical scientists with the data analysis tools capable of handling the datasets of unprocessed data in the most comprehensive and innovative ways.